HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    
What's Up With These Ridiculous Stock Gains?

Steve Reitmeister didn't want me to tell you this. He felt that one strategy's performance stands out so much that... Read on >>
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

RX: Ims Health Inc - Stock News Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Company News |  Zacks Commentary
IMS HEALTH INC (NYSE)
RX 21.52 -0.14 (-0.65%) Vol.  6,066,053 16.00 CST

Nov 20, 2009 IMS Health Up 54.3% Since SmarTrend's Buy Recommendation
Nov 19, 2009 The Masters of the Universe are back – CNNMoney
Nov 17, 2009 RX, ECL, PNK, CBB, PWE and EQR Receives Analytical Coverage fromWallStSense.com
Nov 17, 2009 Par Pharmaceutical granted final approval to market generic Ultram ER
Nov 17, 2009 IMS Health to Release Oncology Quantifier in January 2010
Nov 16, 2009 Par Pharmaceutical Receives Final Approval to Market Generic Ultram(R) ER
Nov 14, 2009 IMS to be Acquired by Private Funds
Nov 12, 2009 BiomedReports: News and FDA Updates for AVANIR (NASDAQ:AVNR), Adamis (OTC:ADMP), IMS (NYSE:RX)
Nov 11, 2009 United States : Mylan subsidiary receives FDA approval for its Lansoprazole DR Capsules ANDA
Nov 11, 2009 Stock research report available on IMS Health (NYSE:RX) from SmarTrend Analytics
Nov 11, 2009 IMS Health to Launch Oncology Quantifier, Delivering Integrated Insights for Enhanced Market Measurement, Commercial Strategies
Nov 11, 2009 IMS Health Enters into Agreement to be Acquired by TPG and CPP Investment Board
Nov 10, 2009 Mylan Receives FDA Approval for Generic Version of Prevacid(R) Through its Subsidiary Matrix Laboratories
Nov 10, 2009 Big Pharma & Biotech
Nov 10, 2009 Big Pharma & Biotech
 
ZACKS COMMENTARY FOR RX
Nov 16, 2009 Zacks Equity Research: Report for RX
Nov 13, 2009 Zacks Blog: IMS to be Acquired by Private Funds
Nov 13, 2009 Zacks Blog: Another Win for Mylan
Nov 10, 2009 Industry Outlook: Big Pharma & Biotech
Nov 10, 2009 Zacks Analyst Interviews: Big Pharma & Biotech
Nov 09, 2009 Zacks Blog: Big Pharma and Biotech
Oct 22, 2009 Zacks Blog: IMS Ahead of Zacks Estimate
Sep 22, 2009 Zacks Blog: Zacks #5 Rank Additions for Tuesday
Jun 17, 2009 Zacks Blog: Zacks #5 Rank Additions for Wednesday
Feb 05, 2009 Zacks Blog: IMS Health Beats 50-day MA

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research